Join the experts for an in-depth discussion on the latest developments in targeted therapies for relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and a look ahead to the upcoming EHA2024 conference.
Credit available for this activity expires: 6/6/2025
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001161?ecd=bdc_podcast_libsyn_mscpedu